Procept Biorobotics Corporation has released a new investor presentation highlighting the company's position in the benign prostatic hyperplasia $(BPH)$ treatment market. The presentation outlines Aquablation Therapy as a unique, automated waterjet solution designed to address a wide range of prostate sizes and shapes, aiming to minimize the trade-off between safety and efficacy found in other surgical interventions. The company identifies a significant unmet need in the BPH market, noting over 8 million patients actively treated and an annual U.S. surgical market opportunity exceeding $20 billion. The presentation also discusses limitations of pharmaceutical therapies, citing minimal symptom relief and potential side effects such as ejaculatory dysfunction, erectile dysfunction, and increased risk of cardiac failure and dementia with long-term use. You can access the full presentation through the link below.